ArticleJournal of orthopaedic surgery and research2017
Peroneal artery perforator flap for the treatment of chronic lower extremity wounds.
Article in Journal of orthopaedic surgery and research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 36 citations in OpenAlex.
- Re-Vision of Geometric Flap Design in Lower Limb Reconstruction: A Comparative Analysis on Perforator Enhancement.Journal of clinical medicine · 2026Article
- Peroneal Artery "Terminal" Perforator Pedicled Flap for Surrounding Soft Tissue Defects: A Retrospective Cohort Study.Orthopedic research and reviews · 2025Article
- Thymoquinone alleviates the accumulation of ROS and pyroptosis and promotes perforator skin flap survival through SIRT1/NF-κB pathway.Frontiers in pharmacology · 2025Article
- Non-Hodgkin's lymphoma involving chronic difficult-to-heal wounds: A case report.World journal of clinical oncology · 2024Article
- Risk factors related to the partial necrosis of the posterior tibial artery perforator-plus fasciocutaneous flap.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2022Article
- Detrimental Effect of Sitagliptin Induced Autophagy on Multiterritory Perforator Flap Survival.Frontiers in pharmacology · 2020Article
- The Microvascular Peroneal Artery Perforator Flap as a "Lifeboat" for Pedicled Flaps.Plastic and reconstructive surgery. Global open · 2019Article
- Reverse first dorsal metacarpal artery flap repair of a right thumb epidermis granuloma: A case study.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundReconstruction of chronic lower extremity wounds remains challenging. These wounds are mainly associated with diabetes mellitus, infections, and osteomyelitis. Although several reconstructive techniques are available, the peroneal artery perforator flap has unique advantages.
methodsIn this study, we discuss our experiences with peroneal artery perforator flaps in 55 patients who had suffered from chronic lower limb wounds. The size of the defect, comorbidities, etiology, flap size, and complications were recorded and analyzed based on a retrospective chart review.
resultsAll 55 flaps survived. In two cases, small superficial necrosis occurred, one of which healed with conservative treatment and the other was reconstructed with split thickness skin grafts. Partial necrosis was observed in nine cases, seven of which were covered with split thickness skin grafts and the remaining two sutured directly after adequate debridement. Vascular compromise was observed in one patient, which was salvaged successfully by performing an exploratory procedure and releasing a few sutures. No complications were seen in the remaining 44 cases.
conclusionThe peroneal artery perforator flap is a reliable option for reconstruction of chronic lower extremity wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.